Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Z-VAD-FMK [161401-82-7]

Z-VAD-FMK [161401-82-7]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-16658B-10mg

Size : 10mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

Z-VAD-FMK (Z-VAD(OH)-FMK) is a well-know pan caspase inhibitor, which does not inhibit ubiquitin carboxy-terminal hydrolase L1 (UCHL1) activity even at concentrations as high as 440 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Z-VAD-FMK Chemische Struktur

CAS. Nr. : 161401-82-7

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Z-VAD-FMK Related Antibodies

Cell Viability Assay
WB
IF
Proliferation Assay
    HFFs stably expressing UL37x1 or empty vector are infected with HCMV in the presence of z-VAD-FMK. At 0, 6 and 12 h.
    C57BL/6 are treated with Concanavalin A (12 μg/g) alone or zVAD (20 μg/g) alone or zVAD (20 μg/g) + Concanavalin A (12 μg/g) at indicated times. The number of apoptotic cells in the zVAD + Concanavalin A treated group is markedly reduced compared with that observed in the ConA-treated group.
    The BMDMs are cultured with different concentrations of zVAD (0, 20, 40, 80, 100 μM) for 24 h.
    After being treated with zVAD (0, 20, 40, 80 μM) for 30 min, the BMDMs are followed by the administration of LPS (100 ng/ml) for 24 h.
    Primary HSCs and LX-2 cells are treated with EA (LX-2 cells: 40 μM; primary HSCs: 45 μM), Ferrostatin-1 (1 μM) and Z-VAD-FMK (10 μM), and cells are stained with PI (red fluorescence) to examine the dead cells.
    In CAL-27 cells, Z-VAD-FMK (50 μM; 4 hours) treatment counteracted the NRC-03-induced cytotoxicity and apoptosis.
    z-VAD-fmk (5 μM; 4 h) weakens CDBEE-induced apoptosis in MGC-803 and HGC-27 cells.
    H1299 and H460 cells are treated with curcumenol with or without Z-VAD-FMK (10 μM) for 24 h, the cell viability is detected.
    Representative image and statistical analyses of JC‐1 staining of KYSE30 cells expressing EV or OTUD1 and treated with DDP or Z‐VAD-FMK (50 μM). Z‐VAD-FMK treatment could not completely inhibit the proapoptotic function of OTUD1.
    In vitro growth of KYSE30 cells expressing EV or OTUD1 and treated with or without Z‐VAD-FMK (50 μM).
    IB further confirmed the activation of the caspase‐dependent apoptotic pathway in OTUD1‐overexpressing cells with AIF ablation, which is diminished by VAD-FMK (50 μM).
    Apoptosis of ECa109 and EC9706 cells treated with SFN (40 μM) and Z-VAD-FMK (20 μM) alone or combination for 48 h is analyzed by flow cytometry.
    When the cells were co-treated with Z-VAD-FMK (50 μM; 24 hours), the F-AgÅPs-induced inhibition of survival of 143B and SJSA-1 is significantly attenuated, as revealed by live/dead cell staining.
    The decreased cleaved caspase-3 and Bax proteins showed that Z-VAD successfully inhibited Chemo-PDT induced apoptosis.

    • Biologische Aktivität

    • Reinheit & Dokumentation

    • Verweise

    • Kundenbewertung

    Z-VAD-FMK (Z-VAD(OH)-FMK) is a well-know pan caspase inhibitor, which does not inhibit ubiquitin carboxy-terminal hydrolase L1 (UCHL1) activity even at concentrations as high as 440 μM.

    Caspase

     

    In Vitro

    Z-VAD-FMK (40 μM) reverses the apoptotic effect exerted by total saponin of Solanum lyratum Thunb (TSSLT) in Hela cells. HeLa cells are pretreated with Z-VAD-FMK (40 μM) for 30 min and exposed to TSSLT (6 μg/mL) for 48 h.

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Z-VAD-FMK Related Antibodies

    Cell Viability Assay

    Cell Line: HeLa cells
    Concentration: 40 μM
    Incubation Time: Prtreated for 30 minutes
    Result: Prevented TSSLT-induced cell death. More than 80% cell survival was observed.

    453.46

    C21H28FN3O7

    161401-82-7

    Solid

    White to light yellow

    O=C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(CF)=O)=O)=O)C(C)C)OCC1=CC=CC=C1

    Room temperature in continental US; may vary elsewhere.

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    In Vitro: 

    DMSO : 100 mg/mL (220.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.2053 mL 11.0263 mL 22.0527 mL
    5 mM 0.4411 mL 2.2053 mL 4.4105 mL
    10 mM 0.2205 mL 1.1026 mL 2.2053 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molaritätsrechner

    • Verdünnungsrechner

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.08 mg/mL (4.59 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 3

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

    • [1]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4.  [Content Brief]

      [2]. Liu HR, et al. Antiproliferative activity of the total saponin of Solanum lyratum Thunb in Hela cells by inducing apoptosis. Pharmazie. 2008 Nov;63(11):836-42.  [Content Brief]

    • [1]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4.

      [2]. Liu HR, et al. Antiproliferative activity of the total saponin of Solanum lyratum Thunb in Hela cells by inducing apoptosis. Pharmazie. 2008 Nov;63(11):836-42.

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.2053 mL 11.0263 mL 22.0527 mL 55.1317 mL
    5 mM 0.4411 mL 2.2053 mL 4.4105 mL 11.0263 mL
    10 mM 0.2205 mL 1.1026 mL 2.2053 mL 5.5132 mL
    15 mM 0.1470 mL 0.7351 mL 1.4702 mL 3.6754 mL
    20 mM 0.1103 mL 0.5513 mL 1.1026 mL 2.7566 mL
    25 mM 0.0882 mL 0.4411 mL 0.8821 mL 2.2053 mL
    30 mM 0.0735 mL 0.3675 mL 0.7351 mL 1.8377 mL
    40 mM 0.0551 mL 0.2757 mL 0.5513 mL 1.3783 mL
    50 mM 0.0441 mL 0.2205 mL 0.4411 mL 1.1026 mL
    60 mM 0.0368 mL 0.1838 mL 0.3675 mL 0.9189 mL
    80 mM 0.0276 mL 0.1378 mL 0.2757 mL 0.6891 mL
    100 mM 0.0221 mL 0.1103 mL 0.2205 mL 0.5513 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Apoptosis
    • Caspase
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Z-VAD-FMK161401-82-7Z-VAD(OH)-FMKCaspasepan-caspaseAntiapoptosisHelacellsInhibitorinhibitorinhibit

    Ihre kürzlich angesehenen Produkte:

    Online-Anfrage

    Your information is safe with us. * Required Fields.

    Massenanfrage

    Inquiry Information

    Produktname:
    Z-VAD-FMK
    Art. -Nr.:
    HY-16658B
    Menge:
    MCE Japan Authorized Agent:

    Kundenbewertung

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    Sie könnten auch an folgenden Produkten interessiert sein:



    Katalog-Nummer
    Beschreibung
    Cond.
    Preis zzgl. MwSt.
    HY-12600-10mg
    AZD5582 [1258392-53-8]
     10mg 
    HY-15989-10mg
    SM-164 [957135-43-2]
     10mg 
    HY-16591-10mg
    Birinapant [1260251-31-7]
     10mg